726 related articles for article (PubMed ID: 26181260)
1. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW
JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260
[TBL] [Abstract][Full Text] [Related]
2. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
Yang M; Xie W; Mostaghel E; Nakabayashi M; Werner L; Sun T; Pomerantz M; Freedman M; Ross R; Regan M; Sharifi N; Figg WD; Balk S; Brown M; Taplin ME; Oh WK; Lee GS; Kantoff PW
J Clin Oncol; 2011 Jun; 29(18):2565-73. PubMed ID: 21606417
[TBL] [Abstract][Full Text] [Related]
3. Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.
Wang X; Harshman LC; Xie W; Nakabayashi M; Qu F; Pomerantz MM; Lee GS; Kantoff PW
J Clin Oncol; 2016 Feb; 34(4):352-9. PubMed ID: 26668348
[TBL] [Abstract][Full Text] [Related]
4. The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.
Anderson-Carter I; Posielski N; Liou JI; Khemees TA; Downs TM; Abel EJ; Jarrard DF; Richards KA
Urol Oncol; 2019 Feb; 37(2):130-137. PubMed ID: 30528885
[TBL] [Abstract][Full Text] [Related]
5. Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy.
Mikkelsen MK; Thomsen FB; Berg KD; Jarden M; Larsen SB; Hansen RB; Brasso K
Scand J Urol; 2017 Dec; 51(6):464-469. PubMed ID: 28831860
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation.
Fujimoto N; Kubo T; Inatomi H; Bui HT; Shiota M; Sho T; Matsumoto T
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):336-40. PubMed ID: 23896625
[TBL] [Abstract][Full Text] [Related]
8. The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.
Harshman LC; Werner L; Tripathi A; Wang X; Maughan BL; Antonarakis ES; Nakabayashi M; McKay R; Pomerantz M; Mucci LA; Taplin ME; Sweeney CJ; Lee GM; Kantoff PW
Prostate; 2017 May; 77(13):1303-1311. PubMed ID: 28762529
[TBL] [Abstract][Full Text] [Related]
9. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M
J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655
[TBL] [Abstract][Full Text] [Related]
10. Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.
Hearn JWD; Xie W; Nakabayashi M; Almassi N; Reichard CA; Pomerantz M; Kantoff PW; Sharifi N
JAMA Oncol; 2018 Apr; 4(4):558-562. PubMed ID: 29049492
[TBL] [Abstract][Full Text] [Related]
11. Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy.
Wu SY; Fang SC; Shih HJ; Wen YC; Shao YJ
Eur J Cancer; 2019 May; 112():109-117. PubMed ID: 30827745
[TBL] [Abstract][Full Text] [Related]
12. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
[TBL] [Abstract][Full Text] [Related]
13. A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer.
Xie W; Drouin S; Nakabayashi M; Pomerantz M; Lee GS; Kantoff PW; Sharifi N
Prostate; 2016 Oct; 76(14):1338-41. PubMed ID: 27325180
[TBL] [Abstract][Full Text] [Related]
14. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
[TBL] [Abstract][Full Text] [Related]
15. The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy.
Hamilton RJ; Ding K; Crook JM; O'Callaghan CJ; Higano CS; Dearnaley DP; Horwitz EM; Goldenberg SL; Gospodarowicz MK; Klotz L
Eur Urol; 2021 Apr; 79(4):446-452. PubMed ID: 33390282
[TBL] [Abstract][Full Text] [Related]
16. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
17. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
JAMA Intern Med; 2014 Sep; 174(9):1460-7. PubMed ID: 25023796
[TBL] [Abstract][Full Text] [Related]
18. Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.
Alsinnawi M; Zhang A; Bianchi-Frias D; Burns J; Cho E; Zhang X; Sowalsky A; Ye H; Slee AE; True L; Porter C; Taplin ME; Balk S; Nelson PS; Montgomery RB; Mostaghel EA
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):560-568. PubMed ID: 30890759
[TBL] [Abstract][Full Text] [Related]
19. SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis.
Rajanala SH; Plym A; Vaselkiv JB; Ebot EM; Matsoukas K; Lin Z; Chakraborty G; Markt SC; Penney KL; Lee GM; Mucci LA; Kantoff PW; Stopsack KH
Carcinogenesis; 2024 Feb; 45(1-2):35-44. PubMed ID: 37856781
[TBL] [Abstract][Full Text] [Related]
20. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]